NeuroScientific Biopharmaceuticals (ASX: NSB) has announced successful clinical results under the TGA Special Access Scheme, with 3 out of 4 patients achieving Clinical Response in real-world treatment of fistulising Crohn’s disease. The biotechnology company reported a 75% success rate for patients with fistulising Crohn’s disease, one of the most severe and treatment-resistant forms of inflammatory bowel disease.
The results validate the company’s StemSmart™ mesenchymal stem cell (MSC) therapy platform in a clinical setting, with the fourth patient demonstrating partial response and ongoing assessments. Clinical Response was defined as either closure of ≥50% of fistula openings or a decrease in fistula discharge of ≥50% as assessed by treating physicians.
Successful Clinical Results Achieved under Special Access Program
NeuroScientific Biopharmaceuticals (ASX: NSB) treated four patients in Cohort 1 under the TGA Special Access Scheme Category B pathway, a regulatory framework designed for serious conditions where no effective conventional therapies exist. The 75% Clinical Response rate represents a significant validation milestone for the StemSmart™ platform, particularly given the debilitating nature of fistulising Crohn’s disease.
The three successful patients achieved measurable fistula closure or discharge reduction, meeting the predefined Clinical Response threshold. The fourth patient showed clinical improvement with partial response, with further assessments currently underway to evaluate ongoing progress.
CEO Nathan Smith emphasised the significance of the results: “These treatment results provide critical validation of the StemSmart™ MSC platform in presenting a potential therapeutic solution to patients with debilitating fistulising Crohn’s disease that have limited effective treatment options. This data, along with our previous clinical trial results in refractory Crohn’s disease, provides a strong foundation for our commercialisation plans for StemSmart™ moving forward.”
Key Results Summary:
- 3 of 4 patients achieved successful Clinical Response
- 1 patient demonstrated partial response with ongoing assessments
- Real-world validation in treatment-resistant fistulising Crohn’s disease population
The data from this Special Access Program will directly inform the study design for NSB’s planned Phase 2 clinical trials, scheduled to commence in 2H 2026. This positions the company to advance regulatory pathways whilst continuing to provide treatment access to patients with limited therapeutic options.
When big ASX news breaks, our subscribers know first
What Do the Clinical Results Mean for NSB Shareholders?
The successful clinical results under the Special Access Scheme de-risk the company’s clinical development pathway and accelerate commercialisation timelines for multiple indications. Investors in (ASX: NSB) can expect Phase 2 trials to commence in 2H 2026, with multi-jurisdictional sites planned across the United States and Australia.
The 75% Clinical Response rate validates StemSmart™ as a platform technology capable of addressing chronic inflammatory conditions beyond Crohn’s disease. NSB has identified four key market opportunities with combined addressable markets exceeding US$59 billion:
| Indication | Market Size | Timeline | Patient Population | NSB Positioning |
|---|---|---|---|---|
| Crohn’s Disease | US$13.8B by 2026 | Phase 2 H2 2026 | Refractory/fistulising | Lead indication |
| Kidney Transplant | US$7.2B by 2030 | Platform expansion | Organ transplant immunosuppression | Post-Crohn’s validation |
| Lung Disorders | US$33B by 2034 | Platform expansion | Chronic inflammatory lung disease | Post-Crohn’s validation |
| Graft-vs-Host Disease | US$5.31B by 2032 | Platform expansion | Post-transplant complications | Post-Crohn’s validation |
The real-world data generated under the Special Access Scheme provides regulatory-grade evidence whilst establishing early commercial validation ahead of formal Phase 2 trials. This dual-purpose approach accelerates time-to-market by generating patient outcomes data that informs trial design and manufacturing scale-up simultaneously.
Platform Expansion Opportunities Beyond Crohn’s Disease:
- Organ transplant immune tolerance applications
- Lung inflammatory disease therapeutics
- Graft-versus-host disease (GvHD) treatment
- Additional chronic inflammatory conditions where conventional therapies demonstrate limited efficacy
The announcement positions NSB as a de-risked clinical-stage biotechnology company with validated technology, clear regulatory pathways, and multiple revenue stream opportunities across a US$59 billion+ addressable market.
Understanding the Special Access Scheme Validation
The TGA Special Access Scheme (SAS) Category B pathway provides a regulatory framework for treating serious or life-threatening conditions where no effective conventional alternatives exist. This pathway allows unapproved therapies to be administered under TGA review and approval when patients have very poor treatment options or little receptivity to conventional treatments.
For fistulising Crohn’s disease patients, the condition represents one of the most severe complications of inflammatory bowel disease, characterised by abnormal connections between organs that cause chronic pain, infection risk, and significantly reduced quality of life. Current approved therapies often fail to achieve sustained remission in this patient population.
SAS Pathway Commercial Value:
- Generates regulatory-grade real-world evidence in controlled clinical setting
- Provides early commercial validation whilst treating patient population with limited options
- Informs Phase 2 trial design with actual patient response data
The clinical results under SAS bridge the gap between early-stage trials and later-phase commercialisation pathways. Previous Phase 2 trial results announced on 16 April 2025 demonstrated that StemSmart™ MSCs were potent, efficacious and safe, providing foundational safety data that supported the SAS applications.
How Does the Special Access Program Support Commercialisation?
The Special Access Scheme generates critical data that accelerates NSB’s commercial pathway whilst addressing immediate unmet medical need. The company is using real-world treatment outcomes to optimise Phase 2 trial design parameters, including dosing protocols, patient selection criteria, and efficacy endpoints.
Manufacturing technology transfer is currently underway to establish commercial-scale production capabilities ahead of Phase 2 trial commencement in H2 2026. This parallel development approach reduces time-to-market by establishing manufacturing infrastructure whilst clinical validation progresses.
Dr Cathy Cole, Chief Medical Officer, highlighted the clinical significance: “The response rate to StemSmart™ MSC treatment seen in these patients in a real-world setting is exceptional, given the serious, debilitating and long-standing adverse nature of their condition. If you consider that for these fistula patients treated with StemSmart™, there were limited treatment options available, then the response to treatment is truly outstanding and offers hope for clinical recovery when there was previously little.”
Phase 2 Preparation Activities Currently Underway:
- Commercial manufacturing technology transfer and scale-up
- Clinical trial development and protocol finalisation
- Regulatory planning for multi-jurisdictional submissions (US and Australia)
- Patient recruitment strategies for refractory Crohn’s disease indication
The company plans to conduct Phase 2 studies in both the United States and Australia, positioning for future commercialisation in these key markets. The Phase 2 indication will target refractory Crohn’s disease, a larger patient population than fistulising disease alone, expanding the commercial opportunity whilst building on the SAS validation data.
StemSmart™ Manufacturing Differentiation
NSB’s StemSmart™ therapy is derived from adult human bone marrow-sourced mesenchymal stem cells processed using a patented manufacturing method designed to improve therapeutic activity and clinical response. The proprietary manufacturing process represents a key competitive advantage in the MSC therapy landscape, where production consistency and cellular potency often vary between manufacturing approaches.
The use of adult bone marrow sources (rather than embryonic stem cells) addresses regulatory and ethical considerations whilst providing a renewable source of therapeutic cells. Early indications from previous Phase 2 trials suggest the manufacturing process produces MSCs that are potent, efficacious and safe across patient populations.
This intellectual property creates a defensible market position as the company advances toward commercialisation. The patented manufacturing process could also support future out-licensing opportunities as the platform expands into additional inflammatory disease indications beyond Crohn’s disease.
What Is the Market Opportunity for StemSmart in Crohn’s Disease Treatment?
Crohn’s disease represents NSB’s lead indication, with a global market valued at approximately US$13.8 billion by 2026. Fistulising Crohn’s disease constitutes the most severe complication of the condition, characterised by abnormal connections between organs or between intestines and skin that cause persistent drainage, pain, and infection risk.
Current treatment options for fistulising Crohn’s disease demonstrate limited efficacy, with many patients experiencing inadequate response to approved biologics and immunosuppressants. This creates a significant unmet medical need for novel therapeutics capable of achieving sustained fistula closure and clinical remission.
The Phase 2 trial strategy targets the broader refractory Crohn’s disease indication, encompassing patients who have failed conventional therapies but may not have developed fistulising complications. This expanded target population increases the commercial opportunity whilst building on the fistulising Crohn’s disease validation data from the Special Access Scheme.
| Pipeline Stage | Indication | Market Size | Timeline | Clinical Need |
|---|---|---|---|---|
| Special Access (Complete) | Fistulising Crohn’s | Subset of US$13.8B | Data available | Most severe complication |
| Phase 2 (Planned) | Refractory Crohn’s | US$13.8B by 2026 | H2 2026 start | Failed conventional therapy |
| Platform Expansion | Kidney Transplant | US$7.2B by 2030 | Post-Crohn’s validation | Immunosuppression alternative |
| Platform Expansion | Lung Inflammatory Disease | US$33B by 2034 | Post-Crohn’s validation | Chronic inflammation |
| Platform Expansion | GvHD | US$5.31B by 2032 | Post-Crohn’s validation | Post-transplant complications |
Three-Phase Commercialisation Roadmap:
- SAS Validation (Current): Real-world data generation in fistulising Crohn’s disease establishes proof-of-concept
- Phase 2 Trials (H2 2026): Multi-jurisdictional studies in refractory Crohn’s disease support regulatory submissions
- Platform Expansion (Post-2027): Validated technology applied to organ transplant, lung disorders, and GvHD indications
The platform technology approach allows NSB to leverage Crohn’s disease clinical validation across multiple inflammatory conditions, potentially reducing development timelines and costs for subsequent indications. Each additional indication represents an incremental revenue opportunity whilst building on the same core manufacturing and regulatory framework.
The next major ASX story will hit our subscribers first
Investment Thesis and Near-Term Catalysts
The successful clinical results establish a de-risked investment case combining validated platform technology, large addressable markets, and clear development pathways. The 75% Clinical Response rate in real-world treatment provides confidence in the therapy’s clinical utility ahead of formal Phase 2 trials.
Near-term catalysts through H2 2026 include Phase 2 trial commencement, completion of commercial manufacturing scale-up, and regulatory submissions in multiple jurisdictions. These milestones position the company for potential partnering or licensing discussions as Phase 2 data becomes available in 2027.
H2 2026 Key Catalysts:
- Phase 2 trial commencement in refractory Crohn’s disease (US and Australia sites)
- Commercial manufacturing technology transfer completion
- Regulatory submissions supporting multi-jurisdictional clinical trials
The company’s total addressable market across platform indications exceeds US$59 billion, with Crohn’s disease serving as the lead indication to validate the technology before expansion into kidney transplant, lung disorders, and graft-versus-host disease applications. The trading halt applied on 9 January 2026 was lifted following this announcement.
CEO Nathan Smith provided a video update on the clinical results and commercialisation strategy, available at https://youtu.be/KTMOejiriVM. The update outlines management’s perspective on the Special Access Scheme outcomes and their implications for the broader StemSmart™ platform development.
Want more Biotech breakthroughs?
Stay ahead in biotechnology with Big News Blasts, a free email service delivering timely biotech news and deep analysis designed for investors focused on innovation within the ASX healthcare and biotech sectors. Join over 20,000 investors who rely on expertly curated alerts to track pivotal clinical trial results, regulatory developments, and market-moving events.
Don’t miss critical updates like the latest StemSmart™ clinical validation—sign up now by clicking the “Free Alerts” button in the menu and get your free subscription to Big News Blasts from StockWire X.